RU2014124101A - Использование тиено- и фуро- пиримидинов и пиримидинов в качестве ингибиторов калиевых каналов - Google Patents

Использование тиено- и фуро- пиримидинов и пиримидинов в качестве ингибиторов калиевых каналов Download PDF

Info

Publication number
RU2014124101A
RU2014124101A RU2014124101/04A RU2014124101A RU2014124101A RU 2014124101 A RU2014124101 A RU 2014124101A RU 2014124101/04 A RU2014124101/04 A RU 2014124101/04A RU 2014124101 A RU2014124101 A RU 2014124101A RU 2014124101 A RU2014124101 A RU 2014124101A
Authority
RU
Russia
Prior art keywords
alkyl
alternatively substituted
alternatively
nhc
alkylene
Prior art date
Application number
RU2014124101/04A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид МАДЖ
Фиона ЧАНЬ
Дерек Эдвард ДЖОН
Саймон Д. ЭДВАРДС
Ричард БЛАНТ
Бэзил ХАРЦУЛАКИС
Линдси БРАУН
Original Assignee
Зеншен Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1119703.5A external-priority patent/GB201119703D0/en
Priority claimed from GBGB1214250.1A external-priority patent/GB201214250D0/en
Application filed by Зеншен Лимитед filed Critical Зеншен Лимитед
Publication of RU2014124101A publication Critical patent/RU2014124101A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2014124101/04A 2011-11-15 2012-11-15 Использование тиено- и фуро- пиримидинов и пиримидинов в качестве ингибиторов калиевых каналов RU2014124101A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1119703.5 2011-11-15
GBGB1119703.5A GB201119703D0 (en) 2011-11-15 2011-11-15 Compounds
GB1214250.1 2012-08-09
GBGB1214250.1A GB201214250D0 (en) 2012-08-09 2012-08-09 Compounds
PCT/GB2012/052842 WO2013072694A1 (en) 2011-11-15 2012-11-15 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors

Publications (1)

Publication Number Publication Date
RU2014124101A true RU2014124101A (ru) 2015-12-27

Family

ID=47222145

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014124101/04A RU2014124101A (ru) 2011-11-15 2012-11-15 Использование тиено- и фуро- пиримидинов и пиримидинов в качестве ингибиторов калиевых каналов

Country Status (15)

Country Link
US (2) US9290511B2 (enExample)
EP (1) EP2780343A1 (enExample)
JP (1) JP2014533259A (enExample)
KR (1) KR20140094603A (enExample)
CN (1) CN104011054B (enExample)
AR (1) AR090037A1 (enExample)
AU (1) AU2012338570A1 (enExample)
BR (1) BR112014011671A2 (enExample)
CA (1) CA2855346A1 (enExample)
IN (1) IN2014MN01183A (enExample)
MX (1) MX2014005935A (enExample)
RU (1) RU2014124101A (enExample)
TW (1) TWI498331B (enExample)
WO (1) WO2013072694A1 (enExample)
ZA (1) ZA201403503B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180722T1 (hr) 2013-06-06 2018-06-15 Astellas Pharma Inc. Spoj benzotiofena
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2545758C1 (ru) * 2014-03-20 2015-04-10 Общество с ограниченной ответственностью "Алион" Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
EP3302057A4 (en) 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2016378723B2 (en) 2015-12-22 2021-09-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
KR102419524B1 (ko) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. 메닌-mll의 가교된 이환식 억제제 및 사용 방법
EP3429591B1 (en) * 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
AU2017388054B2 (en) 2016-12-28 2022-03-24 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
MA49458A (fr) 2017-06-21 2020-04-29 SHY Therapeutics LLC Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
CA3072648A1 (en) * 2017-08-14 2019-02-21 Acesion Pharma Aps Substituted benzimidazoles as potassium channel inhibitors
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
CN108117556A (zh) * 2018-01-15 2018-06-05 王山川 一种细胞周期检查点激酶1抑制剂的合成方法
WO2020085493A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 新規なインダゾール化合物又はその塩
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3897630B1 (en) 2018-12-21 2024-01-10 Celgene Corporation Thienopyridine inhibitors of ripk2
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
WO2022194191A1 (en) * 2021-03-16 2022-09-22 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of kras g12d
JP2024511101A (ja) * 2021-03-22 2024-03-12 アセシオン ファーマ エイピーエス 新規カリウムチャネル阻害剤
TW202304925A (zh) * 2021-03-26 2023-02-01 美商住友製藥腫瘤公司 （呋喃并嘧啶—４—基）哌𠯤化合物及其用途
CN115006468B (zh) * 2022-06-28 2023-06-06 西安外事学院 一种复方中草药生发液及制备方法
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
AU651337B2 (en) * 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
WO1998008845A1 (en) 1996-08-27 1998-03-05 Novartis Ag Herbicidal s-substituted 1,2,4,6-thiatriazines
WO2004011057A1 (en) 1998-02-07 2004-02-05 Advanced Cardiovascular Systems, Inc. Perfusion dilatation catherer with expanded support coil
JP2001097979A (ja) 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
CN1167697C (zh) 1999-09-17 2004-09-22 日产化学工业株式会社 苯并吡喃衍生物
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE10031585A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 2-Aminoalkyl-thieno[2,3-d]pyrimidine
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
IL159218A0 (en) 2001-06-25 2004-06-01 Nissan Chemical Ind Ltd Substituted benzopyran derivatives against arrhythmia
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
EP1425284A2 (en) * 2001-09-11 2004-06-09 Smithkline Beecham Corporation Furo- and thienopyrimidine derivatives as angiogenesis inhibitors
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
GB0315950D0 (en) * 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
KR101186678B1 (ko) * 2003-06-11 2012-09-27 젠션 리미티드 포타슘 채널 억제제로서의 티에노피리미딘 유도체
US7594219B2 (en) 2003-07-24 2009-09-22 International Business Machines Corporation Method and apparatus for monitoring compatibility of software combinations
TWI346112B (en) 2004-02-25 2011-08-01 Nissan Chemical Ind Ltd Benzopyran compound
TW200609237A (en) * 2004-04-12 2006-03-16 Sankyo Co Thienopyridine derivatives
EP1758909A1 (en) * 2004-06-10 2007-03-07 Xention Limited Furanopyrimidine compounds effective as potassium channel inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CN101084224B (zh) 2004-10-21 2013-12-04 美国陶氏益农公司 具有杀真菌活性的噻吩并-嘧啶化合物
JP5173429B2 (ja) 2004-12-09 2013-04-03 ゼンション・リミテッド 化合物
US7576212B2 (en) * 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
WO2006079916A1 (en) 2005-01-26 2006-08-03 Pharmacia & Upjohn Company Llc Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
EP1874780A1 (en) 2005-03-25 2008-01-09 Pharmacia & Upjohn Company LLC 4-piperazinylthieno[2,3-d]pyrimidine compounds as platelet aggregation inhibitors
WO2006103545A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2603041A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
US20080200475A1 (en) 2005-03-28 2008-08-21 Pfizer Inc. 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
EP1899353A1 (en) * 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
CN101268081B (zh) * 2005-09-23 2010-12-29 依柯斯制药 5,6-二甲基噻吩并[2,3-di]嘧啶衍生物，其制备方法和用于抗病毒的包含其的药物组合物
US20070213305A1 (en) * 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
EA200802118A1 (ru) * 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
WO2007146284A2 (en) * 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
DE102006030236A1 (de) 2006-06-30 2008-01-03 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Direktoxidationsbrennstoffzelle für den konvektionsfreien Transport des Brennstoffs und Verfahren zum Betreiben der Brennstoffzelle
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
US8193178B2 (en) * 2007-09-14 2012-06-05 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
MY156226A (en) 2008-02-22 2016-01-29 Otsuka Pharma Co Ltd Benzodiazepine compound and pharmaceutical composition
US20100227853A1 (en) 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
NZ591113A (en) * 2008-08-26 2012-07-27 Boehringer Ingelheim Int Thienopyrimidine linked to phenyl or pyridine via an nh amine for pharmaceutical compositions
TWI334124B (en) * 2008-08-28 2010-12-01 Au Optronics Corp Display drive circuit for flat panel display and driving method for gate lines
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
AU2009291783A1 (en) 2008-09-10 2010-03-18 Alcon Research, Ltd Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
WO2010033127A1 (en) 2008-09-22 2010-03-25 Sionyx, Inc. Response-enhanced monolithic-hybrid pixel
CA2773131C (en) 2009-09-04 2015-07-14 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
ES2544970T3 (es) 2009-10-29 2015-09-07 Bristol-Myers Squibb Company Compuestos de quinuclidina como ligandos del receptor de acetilcolina nicotínico alfa-7
AU2010339531A1 (en) 2009-12-30 2012-08-23 Arqule, Inc. Substituted naphthalenyl-pyrimidine compounds
TW201219401A (en) * 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Also Published As

Publication number Publication date
US9290511B2 (en) 2016-03-22
MX2014005935A (es) 2014-09-04
AU2012338570A1 (en) 2014-07-03
KR20140094603A (ko) 2014-07-30
BR112014011671A2 (pt) 2017-05-30
TW201326178A (zh) 2013-07-01
CA2855346A1 (en) 2013-05-23
ZA201403503B (en) 2016-09-28
CN104011054A (zh) 2014-08-27
EP2780343A1 (en) 2014-09-24
CN104011054B (zh) 2016-08-24
TWI498331B (zh) 2015-09-01
US20140371203A1 (en) 2014-12-18
AR090037A1 (es) 2014-10-15
NZ626199A (en) 2015-04-24
WO2013072694A1 (en) 2013-05-23
IN2014MN01183A (enExample) 2015-07-03
US20160152634A1 (en) 2016-06-02
JP2014533259A (ja) 2014-12-11

Similar Documents

Publication Publication Date Title
RU2014124101A (ru) Использование тиено- и фуро- пиримидинов и пиримидинов в качестве ингибиторов калиевых каналов
ES2959622T3 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para tratar el linfoma
ES2434467T3 (es) Compuestos multicíclicos y métodos para su uso
DE60315265T2 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
JP2016517878A5 (enExample)
KR102399891B1 (ko) 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체
RU2526201C2 (ru) Способ лечения артрита
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
JP2014533259A5 (enExample)
JP2010518026A5 (enExample)
NZ627750A (en) Carbamate compounds and of making and using same
RU2009133336A (ru) Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
RU2017116598A (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
BR112017016193B1 (pt) Derivados de 4h-pirrolo[3,2-c]piridin-4-ona
CA2626623A1 (en) Method of inhibiting flt3 kinase
KR20210149218A (ko) 항암 및 항-증식 활성을 나타내는 n-아실-n'-(피리딘-2-일) 우레아 및 유사체
RU2012104244A (ru) Аналоги tofa, применимые при лечении дерматологических расстройств или состояний
JP2012501313A5 (enExample)
JP2011520832A5 (enExample)
ME02648B (me) Jedinjenje pirazin karboksamida
MX2013005535A (es) Compuesto de 3- (amino-aril) -piridina.
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
WO2009109610A1 (en) Use of nad information inhibitors for the treatment of ischemia-reperfusion injury
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170110